Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton Dickinson and Company

The latest announcement is out from Becton Dickinson ( ($BDX) ). Becton, Dickinson and Company announced that Richard E. Byrd, executive vice presi...

Becton Dickinson announces planned interventional segment leadership transition

Analysts have been eager to weigh in on the Healthcare sector with new ratings on DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)....

Analysts’ Opinions Are Mixed on These Healthcare Stocks: DaVita (DVA), BridgeBio Pharma (BBIO) and Becton Dickinson (BDX)

Dividend aristocrats are S&P 500 companies that have raised their shareholder payouts every year for at least 25 years. The article uses the TipRan...

3 Best Dividend Aristocrat Stocks to Buy Now, 04/02/2026

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics has lodged an application with the Medical Services Advisory...

BCAL seeks Medicare backing for Avantect pancreatic cancer blood test

An update from Abingdon Health PLC ( ($GB:ABDX) ) is now available. Abingdon Health has secured approximately £4.8m of contracts from a US-based cu...

Abingdon Health Wins £4.8m U.S. Contracts for Multiplex Lateral Flow Systems

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics has expanded national access to its Avantect pancreatic and ovarian...

BCAL speeds national rollout of Avantect cancer blood tests

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an announcement. BCAL Diagnostics has disclosed a change in the interests of director Jayne Shaw,...

BCAL Director Jayne Shaw Increases Shareholding via On‑Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an update. BCAL Diagnostics has reported a change in the interests of director Jayne Shaw, who ha...

BCAL Director Jayne Shaw Increases Shareholding Via On-Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an announcement. BCAL Diagnostics director Jayne Shaw has increased her shareholding in the com...

Market Cap	$53.26B	P/E Ratio	12.40
52W High	$213.08	52W Low	$153.18
Div Yield	420.0%	Payout Ratio	308.8%
EPS Growth 3Y	-0.5%	52W Position	3.8%
Overall Score	63	Value Score	95
Quality Score	44	Technical Score	50

EPS Current Est	$12.54	EPS Next Est	$13.73
EPS Growth Est	+9.5%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BDX	$155.46	-1.04%	2.53M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BDX	$155.46	-1.0%	2.53M
3
4
5
6

BDX

BDX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Becton Dickinson and Company Data in Excel

Get Becton Dickinson and Company Data in Excel